Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies - Poll - MDSpire

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • By

  • Jiashun Li

  • Ainikaer Abulaiti

  • Deyu Li

  • Yan Zhao

  • Paerhati Wahafu

  • Maerdan Maimaitiming

  • Shi Qiu

  • Yuxiang Zhang

  • Yaqin An

  • Wenxing Wang

  • Liangquan Shi

  • Maihemuti Yakufu

  • Li Shu

  • Guohua Li

  • Zhen Liu

  • June 22, 2026

  • 0 min

Share

Original Source(s)

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • by Jiashun Li, Ainikaer Abulaiti, Deyu Li, Yan Zhao, Paerhati Wahafu, Maerdan Maimaitiming, Shi Qiu, Yuxiang Zhang, Yaqin An, Wenxing Wang, Liangquan Shi, Maihemuti Yakufu, Li Shu, Guohua Li, Zhen Liu

  • June 22, 2026

Related Content

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research

Dana-Farber Research News 06.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 - 15.

  • by

  • June 1, 2026

  • 38 min
Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis